These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22732343)

  • 1. Decrease of serum sphingosine-1-phosphate levels in hemodialysis patients with secondary hyperparathyroidism treated with cinacalcet.
    Yokoyama K; Ohkido I; Iwamoto T; Ishida M; Urashima M; Hosoya T
    Clin Nephrol; 2012 Jul; 78(1):85-6. PubMed ID: 22732343
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism.
    Komaba H; Koizumi M; Tanaka H; Takahashi H; Sawada K; Kakuta T; Fukagawa M
    Nephrol Dial Transplant; 2012 May; 27(5):1967-9. PubMed ID: 22140124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism.
    Tsuruta Y; Okano K; Kikuchi K; Tsuruta Y; Akiba T; Nitta K
    Clin Exp Nephrol; 2013 Feb; 17(1):120-6. PubMed ID: 22833360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Więcek A
    BMC Nephrol; 2016 Nov; 17(1):176. PubMed ID: 27846800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
    Mercadal Orfila G; Blasco Mascaró I
    Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
    Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study.
    Bonet J; Bayés B; Fernández-Crespo P; Casals M; López-Ayerbe J; Romero R
    Clin Nephrol; 2011 Mar; 75(3):181-7. PubMed ID: 21329627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of tumoral calcinosis after the appropriate control of a deranged mineral and bone metabolism, in conjugation with cinacalcet hydrochloride treatment, in a chronic hemodialysis patient.
    Yamada S; Tsuruya K; Kitazono T
    Ther Apher Dial; 2013 Jun; 17(3):348-9. PubMed ID: 23735152
    [No Abstract]   [Full Text] [Related]  

  • 9. Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients.
    Belozeroff V; Goodman WG; Ren L; Kalantar-Zadeh K
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):673-9. PubMed ID: 19261825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet improves control of secondary hyperparathyroidism in peritoneal dialysis: a multicenter study.
    Portolés J; López-Sánchez P; Bajo MA; Castellano I; del Peso G; Rodríguez JR; Ribera M; Ortigosa A; Selgas R
    Perit Dial Int; 2012; 32(2):208-11. PubMed ID: 22383721
    [No Abstract]   [Full Text] [Related]  

  • 12. [Calcimimetics: physiology, results of preclinical and clinical studies, and perspectives].
    Torres PU
    Nephrol Ther; 2011 Apr; 7(2):99-104. PubMed ID: 21310676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of secondary hyperparathyroidism treatment with cinacalcet on selected adipokines and markers of endothelial injury in hemodialysis patients: a preliminary report.
    Hryszko T; Brzosko S; Rydzewska-Rosołowska A; Koc-Żórawska E; Naumnik B; Myśliwiec M
    Pol Arch Med Wewn; 2012; 122(4):148-53. PubMed ID: 22398419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A patient undergoing chronic dialysis whose renal anemia was successfully corrected by treatment with cinacalcet.
    Oshiro Y; Tanaka H; Okimoto N
    Clin Exp Nephrol; 2011 Aug; 15(4):607-10. PubMed ID: 21455660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
    Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet in the treatment of persistent hyperparathyroidism after kidney transplantation.
    Pinho LR; Ribeiro Santos MJ; Pestana Vasconcelos M
    Clin Nephrol; 2011 Mar; 75(3):263-8. PubMed ID: 21329638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.
    Wheeler DC; London GM; Parfrey PS; Block GA; Correa-Rotter R; Dehmel B; Drüeke TB; Floege J; Kubo Y; Mahaffey KW; Goodman WG; Moe SM; Trotman ML; Abdalla S; Chertow GM; Herzog CA;
    J Am Heart Assoc; 2014 Nov; 3(6):e001363. PubMed ID: 25404192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The influence of side effects related to cinacalcet therapy on compliance in hemodialysis patients suffering from secondary hyperparathyroidism].
    Zwiech R; Chrul S
    Wiad Lek; 2012; 65(3):145-50. PubMed ID: 23289260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the role of calcium-sensing receptor activation.
    Cozzolino M; Mazzaferro S; Messa P
    J Nephrol; 2011; 24 Suppl 18():S38-41. PubMed ID: 21623581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment with cinacalcet in secondary hyperparathyroidism for dialysis patients: The will is good--but what about the evidence?].
    Bárány P; Elinder CG; Samuelsson O
    Lakartidningen; 2013 Aug 21-Sep 3; 110(34-35):1481-3. PubMed ID: 24044187
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.